#RBQMLive
RBQM 2021 On-Demand
Powered by the Pandemic – How Pharma Has Succeeded and How It Will Continue to Embrace Operational Changes Facilitated by COVID-19
Speaker:
Ken Getz, Professor, Tufts Center for the Study of Drug Development
The Evolution from RBM to RBQM – How Far Have Risk-Based Approaches Come in 10 Years and Where Do We Go Next?
Speaker:
Jonathan Rowe, Head of R&D Quality and Risk Management, ZS Associates.
Critical Processes, Critical Data and Critical Thinking. An RBQM Implementation Journey
Speaker:
Nick May, Global Risk-Based Monitoring Strategic Lead, Parexel.
The Application of RBQM to Rare Disease and Small Trials
Speaker:
Jacqueline Gough, Director, Central Monitoring, Alexion Pharmaceuticals.
RBQM Best Practice Defined by Leading Industry Working Groups
Speakers:
Nicole Stansbury, Syneos, Steve Young, CluePoints, Linda Sullivan, MCC, and, Ann Meeker O'Connell, Vertex Pharmaceuticals.
The Future of Clinical Trials is Now
Speaker:
Sy Pretorius, President, Clinical Development and Chief Medical Officer, Parexel.
Paving the Way for Centralized Monitoring Success at Pfizer
Speaker:
Lynne Cesario, Global Risk-Based Monitoring Program Lead, Pfizer.
Applying the Principles of RBQM to Data Management
Speakers:
Steve Young, Chief Scientific Officer, CluePoints, and Patrick Nadolny, Global Head, Clinical Data Management, Sanofi.
2030: An RBQM Odyssey - RBQM in Clinical Trials of the Future
Speaker:
Lukasz Bojarski, Head of Centralized Monitoring, AstraZeneca.
Has RBQM Lived up to TransCelerate's Expectations? Ask the Experts!
Speakers:
Brett Wilson, Pfizer, Jacqueline Gough, Alexion, Stephanie Clark, Janssen, Mary Arnould, Astellas, and Esther Huffman-O'Keefe, Regeneron.
